Physician profile
Dustin Blue Manders
NPI 1326241324
$171,322.60
in general payments reported to CMS, 2019-2025
38 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,120 · 2020: $11K · 2021: $5,583 · 2022: $41K · 2023: $17K · 2024: $50K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Food and Beverage: $5,288 · Travel and Lodging: $3,077 · Consulting Fee: $3,069 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,250.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,658.75 |
| Food and Beverage | $5,287.69 |
| Travel and Lodging | $3,076.50 |
| Consulting Fee | $3,068.75 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $136,789.51 | 2020-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals Lp | $15,575.72 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Eisai INC. | $15,400.13 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $765.24 | 2022-2025 | Precisetumor, Myrisk |
| Clovis Oncology, INC. | $371.66 | 2019-2021 | |
| Dilon Technologies, INC. | $313.54 | 2024 | Hemoblast Bellows |
| Merck Sharp & Dohme LLC | $294.44 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Genmab U.S., INC. | $247.93 | 2022-2024 | Tivdak |
| Ethicon US, LLC | $190.13 | 2020-2025 | Stratafix, Vistaseal, Enseal |
| Biom'Up France Sas | $140.13 | 2020 | |
| Novartis Pharmaceuticals Corporation | $124.76 | 2025 | |
| Janssen Biotech, INC. | $121.28 | 2024-2025 | Rybrevant, Erleada |
| Hologic Sales and Service, LLC | $107.09 | 2025 | Myosure Tissue Removal Device, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $106.89 | 2024-2025 | |
| Genentech USA, INC. | $102.26 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $69.36 | 2023-2024 | Orserdu, Elzonris |
| Abbvie INC. | $52.84 | 2024 | |
| Tesaro, INC. | $48.58 | 2019 | |
| Taiho Oncology, INC. | $42.89 | 2024-2025 | |
| Sobi, INC | $42.59 | 2025 | |
| Pfizer INC. | $40.04 | 2025 | |
| Lilly USA, LLC | $37.13 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Deciphera Pharmaceuticals INC. | $27.47 | 2025 | Qinlock, Romvimza |
| Daiichi Sankyo INC. | $25.94 | 2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $25.35 | 2025 | |
| Incyte Corporation | $25.29 | 2024 | Jakafi |
| Azurity Pharmaceuticals, INC. | $24.71 | 2025 | Danziten |
| Gilead Sciences, INC. | $23.40 | 2024 | |
| Geron Corporation | $23.18 | 2025 | Rytelo |
| Seagen INC. | $22.90 | 2023 | Tukysa |
| Menarini Silicon Biosystems, INC. | $20.87 | 2024 | |
| Emd Serono, INC. | $19.03 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $17.94 | 2025 | Caldolor |
| Genzyme Corporation | $17.73 | 2025 | |
| Amgen INC. | $17.56 | 2019 | |
| Astellas Pharma US INC | $16.58 | 2023 | Veozah |
| Aspira Women'S Health INC | $15.98 | 2019 | |
| Beigene USA, INC. | $14.53 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Manders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.